COMPANY
Vera Therapeutics
FDA-approved therapeutic company Clinical Phase 3
Since the raise (Dec 10, 2025): 10 of 10 open jobs were first seen after it.
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Manager, Regulatory Operations | Remote | Oct 19, 2026 | Oct 20, 2026 |
| Senior Director, Medical and Scientific Communications | Remote | Oct 15, 2026 | Oct 16, 2026 |
| Senior Clinical Trial Manager | Remote | Oct 14, 2026 | Oct 14, 2026 |
| Senior Director, Pharmacovigilance Operations & Compliance | Remote | Oct 12, 2026 | Oct 13, 2026 |
| Associate Director, Commercial Analytics | Remote | Oct 3, 2026 | Oct 9, 2026 |
Trial and FDA signals
- Drug approval + hiring FDA novel approval for TRUTAKNA (BLA 761486, Jul 7, 2026); since then posted 5 manufacturing/quality or commercial roles. FDA BLA 761486 (Jul 7, 2026)
Evidence (1 event)
- Jul 7, 2026 · FDA BLA 761486
openFDA drugsfda: application_number=BLA761486; sponsor_name='VERA THERAPEUTICS INC.'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260707; submission_class_code=TYPE 1; brand_name=['TRUTAKNA']
- Jul 7, 2026 · FDA BLA 761486
Timeline
- Board tracked Radar started tracking this company’s job board (10 open jobs at last check). source ↗
- FDA FDA New drug/biologic (novel): TRUTAKNA (atacicept-vymj) — BLA761486, Jul 7, 2026. Applicant at approval: Vera Therapeutics, Inc. Accelerated approval. source ↗
- Raise Follow-on offering: $261M (total, as published), announced Dec 10, 2025. Source: company release on GlobeNewswire. source ↗
- Trial start Phase 2: Atacicept in Multiple Glomerular Diseases source ↗
- Debt Debt financing: $500M (up to, as announced), announced Jun 3, 2025. Source: company release on GlobeNewswire. source ↗
- Trial start Phase 2: Monthly Dosing of Atacicept in IgAN source ↗
- Trial start Phase 2: A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept source ↗
- Raise Follow-on offering: $300M (total, as published), announced Oct 30, 2024. Source: company release on GlobeNewswire. source ↗
- Trial start Phase 3: Atacicept in Subjects With IgA Nephropathy source ↗
- Trial start Phase 3: Atacicept in Subjects With Active Lupus Nephritis (COMPASS) source ↗
- Trial start Phase 2: A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients source ↗
Upcoming milestones
- 2027-11 (ESTIMATED) · Phase 2 · Atacicept in Multiple Glomerular Diseases · NCT06983028
- May 21, 2031 (ESTIMATED) · Phase 2 · A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept · NCT06674577
Open jobs 10
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Manager, Regulatory Operations | Remote | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Senior Director, Medical and Scientific Communications | Remote | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Senior Clinical Trial Manager | Remote | Oct 14, 2026 | Oct 14, 2026 | Senior |
| Senior Director, Pharmacovigilance Operations & Compliance | Remote | Oct 12, 2026 | Oct 13, 2026 | Senior |
| Associate Director, Commercial Analytics | Remote | Oct 3, 2026 | Oct 9, 2026 | Senior |
| Rare Disease Sales Specialist (Los Angeles East Territory) | Remote | Sep 4, 2026 | Oct 9, 2026 | Mid |
| Associate Director of Commercial Operations | Remote | Sep 4, 2026 | Oct 9, 2026 | Senior |
| Senior Director, Human Resources Business Partner | Remote | Aug 11, 2026 | Oct 9, 2026 | Senior |
| Associate Director, Drug Substance Manufacturing – Upstream Process | Remote | Aug 4, 2026 | Oct 9, 2026 | Senior |
| Associate Director, Clinical Quality Assurance | Remote | Jun 23, 2026 | Oct 9, 2026 | Senior |
Funding
- Follow-on offering: $261M (total, as published), announced Dec 10, 2025. Source: company release on GlobeNewswire. source ↗
- Follow-on offering: $300M (total, as published), announced Oct 30, 2024. Source: company release on GlobeNewswire. source ↗
- Debt financing: $500M (up to, as announced), announced Jun 3, 2025. Source: company release on GlobeNewswire. source ↗
Clinical trials (lead sponsor) 6
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT04716231 | Atacicept in Subjects With IgA Nephropathy | Phase 3 | Active, not recruiting | Jun 29, 2023 | May 15, 2025 (actual) |
| NCT06983028 | Atacicept in Multiple Glomerular Diseases | Phase 2 | Recruiting | Jul 7, 2025 | 2027-11 (estimated) |
| NCT06674577 | A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept | Phase 2 | Enrolling by invitation | Dec 1, 2024 | May 21, 2031 (estimated) |
| NCT07020923 | Monthly Dosing of Atacicept in IgAN | Phase 2 | Active, not recruiting | May 29, 2025 | 2026-09 (estimated) |
| NCT05609812 | Atacicept in Subjects With Active Lupus Nephritis (COMPASS) | Phase 3 | Withdrawn | Nov 2, 2022 | Mar 15, 2026 (estimated) |
| NCT04294472 | A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients | Phase 2 | Completed | Aug 5, 2020 | Feb 10, 2022 (actual) |
FDA records (last 2 years)
- FDA New drug/biologic (novel): TRUTAKNA (atacicept-vymj) — BLA761486, Jul 7, 2026. Applicant at approval: Vera Therapeutics, Inc. Accelerated approval. source ↗
Raises and investors new
- InvestorListed in the portfolio of Sofinnova Investments (captured Oct 12, 2026). portfolio page ↗
Connect
See your connections at Vera Therapeutics on LinkedIn (search by name, results not checked)